iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, announced today it has provided SecondLook Digital ®, the company’s digital mammography Computer-Aided Detection (CAD) software, for an Italian feasibility study.
The study, “Using computer-assisted diagnosis (CAD - Computer Aided Detection) in the current practice of mammography screening programs,” will compare the accuracy and cost effectiveness of conventional double reading to single reading with CAD for mammography screenings and will enroll 45,000 patients at six sites throughout Italy.
“This study will help us gather the necessary information to systematically change the way we perform mammography screenings in this country. Double read scans are outdated and cumbersome when compared to the more advanced screening technologies available today,” said Giorgio Benea, M.D., Ospedale del Delta in Lagosanto, Italy and Principal Investigator for the study. “Cutting-edge technologies, like SecondLook Digital, can improve the detection of breast cancer, allowing for earlier treatment and improved patient outcomes.”
SecondLook provides a computerized second review of mammograms. This “second” or closer look allows radiologists to recognize subtle changes in breast tissue that could require a more thorough examination to confirm the presence of cancer. Additionally, SecondLook provides improved workflow for mammography centers by enabling a radiologist to more quickly identify and review areas of concern and work more efficiently.“We are honored that Italy has chosen SecondLook Digital as the benchmark technology for this important study,” said Ken Ferry, President and CEO of iCAD. “With more than 25 published studies supporting the use of CAD in conjunction with digital mammography, we are confident the results of the study will help establish single read with CAD as the nationally accepted method for mammography screening.” About iCAD, Inc. iCAD is an industry-leading provider of advanced image analysis, workflow solutions and radiation therapies for the early identification and treatment of common cancers. iCAD offers a comprehensive range of high-performance, upgradeable CAD solutions for mammography and advanced image analysis and workflow solutions for Magnetic Resonance Imaging, for breast and prostate cancers and Computed Tomography for colorectal cancer. iCAD’s Xoft System, offers radiation treatment for early-stage breast cancer that can be administered in the form of intraoperative radiation therapy or accelerated partial breast irradiation. The Xoft System is also cleared for the treatment of non-melanoma skin cancer and endometrial cancer. For more information, call 877-iCADnow, or visit www.icadmed.com. "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts